Skip to main content

Table 1 Baseline (pre-treatment) characteristics of SCMs without neck muscle spasm and those with neck muscle spasm

From: Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy

Variables

SCMs without neck muscles spasm

SCMs with neck muscles spasm

P value

Group number

254

50

 

Sex

  

0.003

 Male

199 (78.35%)

29 (58.00%)

 

 Female

55 (21.65%)

21 (42.00%)

 

Age (years)

  

0.471

  ≤ 41

131 (51.57%)

23 (46.00%)

 

  > 41

123 (48.43%)

27 (54.00%)

 

T stage

  

0.356

 T1–2

61 (24.02%)

9 (18.00%)

 

 T3–4

193 (75.98%)

41 (82.00%)

 

N stage

  

0.002

 N0–1

127 (50.00%)

13 (26.00%)

 

 N2–3

127 (50.00%)

37 (74.00%)

 

Smoking status

  

0.799

 Yes

86 (33.86%)

16 (32.00%)

 

 No

168 (66.14%)

34 (68.00%)

 

Drinking status

  

0.851

 Yes

38 (14.96%)

8 (16.00%)

 

 No

216 (85.04%)

42 (84.00%)

 

Induction chemotherapy

  

0.839

 Yes

123 (48.43%)

25 (50.00%)

 

 No

131 (50.57%)

25 (50.00%)

 

Concurrent chemotherapy

  

0.851

 Yes

216 (85.04%)

42 (84.00%)

 

 No

38 (14.96%)

8 16.00%)

 

Neck dissection

  

0.324

 Yes

8 (3.15%)

3 (6.00%)

 

 No

246 (96.85%)

47 (94.00%)

 

D mean

50.54 Gy (38.04 Gy – 58.91 Gy)

62.05 Gy (61.22 Gy – 62.35 Gy)

< 0.001

D min

2.68 Gy (1.04 Gy – 29.44 Gy)

35.88 Gy (30.35 Gy – 39.58 Gy)

< 0.001

D max

68.82 Gy (66.24 Gy – 71.46 Gy)

70.80 Gy (68.58 Gy −72.51 Gy)

0.048

V20a

84.94% (61.87% – 100%)

100% (100% – 100%)

< 0.001

V25

81.70% (59.84% – 100%)

100% (100% – 100%)

< 0.001

V30

79.52% (57.88% – 99.99%)

100% (100% – 100%)

< 0.001

V35

77.57% (56.23% – 99.76%)

100% (99.88% – 100%)

< 0.001

V40

75.57% (54.40% – 98.99%)

99.89% (99.22% – 100.00%)

< 0.001

V45

74.00% (52.43% – 96.44%)

99.07% (97.67% – 99.70%)

< 0.001

V50

70.87% (47.81% – 90.72%)

96.32% (93.59% – 98.32%)

< 0.001

V55

64.00% (41.94% – 78.86%)

87.74% (84.56% – 91.79%)

< 0.001

V60

39.02% (23.11% – 52.10%)

68.33% 64.01% – 72.25%)

< 0.001

V65

8.16% (0.97% – 20.59%)

35.01% (23.10% – 41.22%)

< 0.001

V70

0.00% (0.00% – 0.76%)

1.66% (0.00% – 13.78%)

< 0.001

V75

0.00% (0.00% – 0.00%)

0.00% (0.00% – 0.00%)

0.010

V80

0.00% (0.00% – 0.00%)

0.00% (0.00% – 0.00%)

0.537

D20b

63.12 Gy (60.59 Gy – 65.28 Gy)

66.74 Gy (64.93 Gy – 68.01 Gy)

< 0.001

D25

62.39 Gy (59.74 Gy – 64.31 Gy)

66.04 Gy (64.30 Gy – 67.35 Gy)

< 0.001

D30

61.69 Gy (58.95 Gy – 63.39 Gy)

65.27 Gy (63.61 Gy – 66.61 Gy)

< 0.001

D35

60.76 Gy (57.74 Gy – 62.53 Gy)

64.76 Gy (63.05 Gy – 65.92 Gy)

< 0.001

D40

59.79 Gy (55.88 Gy – 61.70 Gy)

63.97 Gy (62.68 Gy – 64.85 Gy)

< 0.001

D45

59.06 Gy (53.84 Gy – 61.01 Gy)

63.23 Gy (62.31 Gy – 64.05 Gy)

< 0.001

D50

58.17 Gy (49.85 Gy – 60.38 Gy)

62.48 Gy (61.59 Gy – 63.14Gy)

< 0.001

D55

57.52 Gy (38.66 Gy – 59.55 Gy)

61.75 Gy (61.01 Gy – 62.44 Gy)

< 0.001

D60

56.26 Gy (27.73 Gy – 58.83 Gy)

61.10 Gy (60.35 Gy – 61.67 Gy)

< 0.001

D65

54.85 Gy (16.57 Gy – 58.14 Gy)

60.22 Gy (59.61 Gy – 60.86 Gy)

< 0.001

D70

51.52 Gy (9.49 Gy – 57.19 Gy)

59.80 Gy (58.47 Gy – 57.81 Gy)

< 0.001

D75

43.68 Gy (5.57 Gy – 56.15 Gy)

58.42 Gy (57.51 Gy – 59.37 Gy)

< 0.001

D80

35.34 Gy (3.21 Gy – 54.78 Gy)

57.21 Gy (56.01 Gy – 58.29 Gy)

< 0.001

  1. Abbreviations: SCM sternocleidomastoid muscle, Dmean Mean dose to the sternocleidomastoid muscle, Dmax Maximum dose to the sternocleidomastoid muscle; V20a is the percentage of the sternocleidomastoid muscle volume that received more than 20 Gy; D20b is the dose to 20% of the sternocleidomastoid muscle volume; the other dosimetric parameters are reported in a similar manner